LipiFlow®, LipiView®

Structured Credit$50 Million

Feb 2013

MarketerTearScience

TearScience was the first company to offer a device-based solution for the diagnosis and treatment of Evaporative Dry Eye Disease, a $10 billion market opportunity in North America. The TearScience system includes both a diagnostic device (LipiView) and a therapeutic device (LipiFlow) to enable ophthalmologists to treat the root cause of lipid deficient evaporative dry eye.

Background

TearScience is a private company commercializing a novel device-based diagnostic and treatment for dry eye, a condition that affects over 25 million patients in the US with over $4 billion spent per year on treatment. HCR invested $50 million in a senior secured loan in 2013, which enabled the company to expand commercial efforts and grow the business. HCR subsequently led an equity financing in March 2016 to support continued growth.

News